Peer-influenced content. Sources you trust. No registration required. This is HCN.

Cleveland Clinic Journal of MedicineAnemia of Chronic Kidney Disease: Will New Agents Deliver on Their Promise?

A newly developed prolyl hydroxylase inhibitor (agents that increase endogenous erythropoietin production) holds the promise of improving outcomes for patients with anemia of chronic kidney disease. Randomized controlled trials have found these drugs to be at least as effective as erythropoiesis-stimulating agents.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form